Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT03789916

SAPT Versus DAPT in Incomplete Revascularization After CABG

Led by Campus Bio-Medico University · Updated on 2022-07-21

800

Participants Needed

1

Research Sites

417 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study aims to compare the efficacy of dual antiplatelet therapy (DAPT) over single antiplatelet therapy (SAPT) in patients with incomplete revascularization after coronary artery bypass graft surgery (CABG). Before hospital discharge, patients will be 1:1 randomized to SAPT (acetylsalicylic acid 100 mg/die) or DAPT (acetylsalicylic acid 100 mg/die + ticagrelor 90 mg bis in die). DAPT will be continued for 12 months, and ticagrelor will be withdrawn thereafter. Primary endpoint is the evaluation of cardiac-related mortality at 5 years from hospital discharge.

CONDITIONS

Official Title

SAPT Versus DAPT in Incomplete Revascularization After CABG

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients undergoing coronary artery bypass graft surgery, with or without cardiopulmonary bypass or associated cardiac procedures
  • Incomplete myocardial revascularization, based on anatomical or functional criteria
  • Provided informed consent to participate
Not Eligible

You will not qualify if you...

  • Acute coronary syndrome within 12 months before surgery
  • Receiving dual antiplatelet therapy at hospital admission
  • Planned procedure to complete myocardial revascularization (e.g., hybrid approach)
  • Intolerance or inability to take acetylsalicylic acid or ticagrelor
  • Preoperative atrial fibrillation
  • Impaired compliance
  • Planned pregnancy
  • History of gastrointestinal bleeding
  • Chronic kidney disease with eGFR less than 30 mL/min/1.73 m2
  • Chronic liver disease
  • Severe heart failure at hospital admission
  • Active malignancy
  • Alcohol abuse
  • Any condition not compatible with the treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Università Campus Bio-Medico di Roma

Rome, Italy, 00128

Actively Recruiting

Loading map...

Research Team

A

Antonio Nenna, MD

CONTACT

M

Massimo Chello, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here